Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
ELTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.34 - $11.45
Previous CloseN/A
Volume37.28K
Average Volume (3M)44.23K
Market Cap
$84.39M
Enterprise Value$63.49M
Total Cash (Recent Filing)-$6.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 14, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.45
Shares Outstanding15,953,524
10 Day Avg. Volume57,772
30 Day Avg. Volume44,229
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-54.27
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$11.00Price Target Upside107.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Elicio Therapeutics News
PremiumCompany Announcements
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline
PremiumCompany Announcements
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer
PremiumCompany Announcements
Elicio Therapeutics Advances with New Clinical Updates---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive results for ELI-002 7P could drive meaningful share price appreciation and might prove sufficient to catalyze partnership.
Potential RevenuePotential successful commercialization of ELI-002 7P across multiple solid tumor types could yield peak revenues exceeding $550M in the U.S. alone by 2035.
Bears Say
Clinical Trial RisksRisks include failure to generate clear proof-of-concept clinical efficacy data showing the impact of ELI-002 7P in KRAS-mutated cancers.
Financial PerformanceElicio Therapeutics reported a net loss of $4.25 per share—wider than previously estimated net loss of $3.62 per share.
---
Ownership Overview
35.35% Insiders
1.92% Mutual Funds
0.34% Other Institutional Investors
60.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $3.34 and its highest was $11.45 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $84.39M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 32 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Mar 31, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.83 by -$0.24.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 15,953,524 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.83. Following the earnings report the stock price went down -20.924%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
---
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (107.94% Upside)
$11.00 (107.94% Upside)
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.5%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.88%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
3.80%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
---
ELTX Stock 12 Month Forecast
Average Price Target
$11.00
▲(107.94% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
ALX Oncology Holdings
―
Best Analysts Covering ELTX
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
-10.91%
reiterated a buy rating 10 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -10.91% per trade.
---